{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:26:07Z","timestamp":1778343967383,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>An increased number of elderly individuals affected by rheumatoid arthritis (RA) has been reported, including both patients with RA onset in advanced age and patients aged with the disease. In this registry-based study, we aimed to analyze the retention rate and cause of discontinuation of biologic (b) and targeted synthetic (ts)-disease-modifying anti-rheumatic drugs (DMARDs) in RA patients over 65\u2009year old.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>RA patients enrolled in the Italian GISEA registry and starting a b- or a ts-DMARD over 65\u2009years of age were included. Demographic, clinical, serologic, and therapeutic features were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,221 elderly RA patients were analyzed (mean age 71.6\u2009\u00b1\u20095.2\u2009years). RA was diagnosed before 65\u2009years in 72.5% of cases, a 60.6% of patients experienced a previous b- or ts-DMARD. In patients older than 65 initiating a new b- or ts-DMARDS, tumor necrosis factor alpha inhibitors (TNFi) were prescribed in 29.6% of patients, abatacept in 24.8%, anti-interleukin 6 receptor antagonists (anti-IL6R) in 16.3%, Janus kinases inhibitors (JAKi) in 24.9%, and rituximab in 4.4%. The main causes of discontinuation were primary or secondary inadequate responses (66.1%). The median retention rate for all treatments was 181.3\u2009weeks. A statistically higher retention rate was observed for abatacept when compared to TNFi (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), JAKi (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), and anti-IL6R (p\u2009&amp;lt;\u20090.001), and for TNFi vs. JAKi (<jats:italic>p<\/jats:italic>\u2009=\u20090.013).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We described, in a real-life setting, elderly RA patients treated with a biologic or a ts-DMARD in Italy. Loss of efficacy was the main cause of discontinuation, and the DMARD safety profile suggests that age does not contraindicate their use. Our study reinforced that the control of disease activity is mandatory.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1349533","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:58:04Z","timestamp":1710133084000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry"],"prefix":"10.3389","volume":"11","author":[{"given":"Andreina","family":"Manfredi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bazzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ennio Giulio","family":"Favalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Scalvini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Garufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Gorla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","article-title":"Rheumatoid arthritis in the elderly: characteristics and treatment considerations","volume":"19","author":"Serhal","year":"2020","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/art.10897","article-title":"Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification","volume":"48","author":"Rasch","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","article-title":"The influence of ageing on the development and management of rheumatoid arthritis","volume":"9","author":"Boots","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3899\/jrheum.170773","article-title":"Rheumatologists\u2019 views and experiences in managing rheumatoid arthritis in elderly patients: a qualitative study","volume":"45","author":"Nawrot","year":"2018","journal-title":"J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e33559","DOI":"10.1371\/journal.pone.0033559","article-title":"Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs","volume":"7","author":"Konrat","year":"2012","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/annrheumdis-2020-217520","article-title":"EULAR\/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries","volume":"79","author":"Meisters","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jbspin.2014.06.011","article-title":"Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register","volume":"81","author":"Sebastiani","year":"2014","journal-title":"Joint Bone Spine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/MAS-130255","article-title":"Statistical methods in medical research","volume":"8","author":"Chan","year":"2013","journal-title":"Model Assist Stat Appl"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/ijerph20031789","article-title":"Differentiating between seronegative elderly-onset rheumatoid arthritis and polymyalgia rheumatica: a qualitative synthesis of narrative reviews","volume":"20","author":"Ohta","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1083879","DOI":"10.3389\/fmed.2022.1083879","article-title":"Elderly-onset rheumatoid arthritis vs. polymyalgia rheumatica: differences in pathogenesis","volume":"9","author":"Wu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/rheumatology\/kel144","article-title":"Are rheumatologists\u2019 treatment decisions influenced by patients\u2019 age?","volume":"45","author":"Fraenkel","year":"2006","journal-title":"Rheumatology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/mr\/roab087","article-title":"Treatment strategies for elderly-onset rheumatoid arthritis in the new era","volume":"32","author":"Sugihara","year":"2022","journal-title":"Mod Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00296-020-04770-7","article-title":"Disease-modifying drug retention rate according to patient age in patients with early rheumatoid arthritis: analysis of the ESPOIR cohort","volume":"41","author":"Mathieu","year":"2021","journal-title":"Rheumatol Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0216624","DOI":"10.1371\/journal.pone.0216624","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -the ANSWER cohort study","volume":"14","author":"Ebina","year":"2019","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1093\/rheumatology\/keab223","article-title":"COVID-19 vaccination and antirheumatic therapy","volume":"60","author":"Arnold","year":"2021","journal-title":"Rheumatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1093\/rheumatology\/keac624","article-title":"COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis","volume":"62","author":"Naveen","year":"2023","journal-title":"Rheumatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"168663","DOI":"10.1172\/jci.insight.168663","article-title":"Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies","volume":"8","author":"Klebanoff","year":"2023","journal-title":"JCI Insight"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1007\/s10067-021-05734-3","article-title":"Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry","volume":"40","author":"Sebastiani","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3899\/jrheum.111125","article-title":"Longterm retention of tumor necrosis factor-\u03b1 inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors","volume":"39","author":"Iannone","year":"2012","journal-title":"J Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e31161","DOI":"10.1097\/MD.0000000000031161","article-title":"Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis","volume":"101","author":"Temmoku","year":"2022","journal-title":"Medicine"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/rheumatology\/ker281","article-title":"Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry","volume":"50","author":"Busquets","year":"2011","journal-title":"Rheumatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","article-title":"Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology biologics register","volume":"59","author":"Bechman","year":"2020","journal-title":"Rheumatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.arr.2010.08.004","article-title":"Age effects on B cells and humoral immunity in humans","volume":"10","author":"Frasca","year":"2011","journal-title":"Ageing Res Rev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.55563\/clinexprheumatol\/f7ff6q","article-title":"The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age","volume":"40","author":"Specker","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/medicina57090914","article-title":"Sustained long-term retention rates of abatacept in combination with conventional synthetic disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis","volume":"57","author":"Sato","year":"2021","journal-title":"Medicina (B Aires)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.3390\/jcm12144585","article-title":"Drug retention rates and the safety of Janus kinase inhibitors in elderly patients with rheumatoid arthritis","volume":"12","author":"Temmoku","year":"2023","journal-title":"J Clin Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"103357","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.55563\/clinexprheumatol\/a9gskx","article-title":"Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines","volume":"40","author":"Novella-Navarro","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.22540\/JFSF-08-044","article-title":"Sarcopenia in rheumatoid arthritis. A narrative review","volume":"8","author":"Moschou","year":"2023","journal-title":"J Frailty Sarcopenia Falls"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1349533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:58:07Z","timestamp":1710133087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1349533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":33,"alternative-id":["10.3389\/fmed.2024.1349533"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1349533","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"article-number":"1349533"}}